Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: Comparison between enzyme activity and gene expression

European Journal of Cancer

Volumn 39, Issue 6, 2003, Pages 822-828

  Porsin, B ^a   Formento, J L ^a   Filipski, E ^b   Etienne, M C ^a   Francoual, M ^a   Renee N ^a   Magne N ^a   Levi F ^b   Milano, Gerard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Chronopharmacology; Circadian rhythm; Dihydropyrimidine dehydrogenase; Drug metabolism

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; LIVER ENZYME;

ANIMAL TISSUE; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME REGULATION; GENE EXPRESSION REGULATION; LEUKOCYTE COUNT; LIVER; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CIRCADIAN RHYTHM; DIHYDROURACIL DEHYDROGENASE (NADP); ENZYME-LINKED IMMUNOSORBENT ASSAY; LIVER; MALE; MICE; OXIDOREDUCTASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0037375992     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00598-1     Document Type: Article

References (31)

1. Diasio R.B., Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16:1989;215-237.
2. Fleming R., Milano G., Thyss A.et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patient. Cancer Res. 52:1992;2899-2902.
3. Fleming R.A., Milano G., Gaspard M.H.et al. Dihydropyrimidine deshydrogenase activity in cancer patients. Eur. J. Cancer. 29:1993;740-744.
4. Beck A., Etienne M.C., Cheradame S.et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur. J. Cancer. 30:1994;1517-1522.
5. Etienne M.C., Cheradame S., Fischel J.L.et al. Response to fluorouracil therapy in cancer patients. the role of tumoral dihydropyrimidine dehydrogenase activity J. Clin. Oncol. 13:1995;1663-1670.
6. Milano G., Etienne M.C., Pierrefite V., Barberi-Heyob M., Deporte-Fety R., Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil related toxicity. Br. J. Cancer. 79:1999;627-630.
7. Grem J.L., Danenberg K.D., Behan K.et al. Thymidine kinase, thymidylate synthase and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer drug screen. Clin. Cancer Res. 7:2001;999-1009.
8. Harris B.E., Song R., He Y.J., Soong S.J., Diasio R.B. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase, possible relevance to fluoropyrimidine chemotherapy. Biochem. Pharmacol. 37:1988;4759-4762.
9. Harris B.E., Song R., Soong S.J., Diasio R.B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluororuracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50:1990;197-201.
10. Grem J.L., Yee L.K., Venzon D.J., Takimoto C.H., Allegra C.J. Inter-and intra-individual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother. Pharmacol. 40:1997;117-125.
11. Balsalobre A., Damiola F., Schibler U. A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell. 93:1998;929-937.
12. Tanaka-Nozaki M., Onda M., Tanaka N., Kato S. Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels. Clin. Cancer Res. 7:2001;2783-2787.
13. Uetake H., Ichikawa W., Takechi T., Fukushima M., Nihei Z., Sugihara K. Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clin. Cancer Res. 5:1999;2836-2839.
14. Castillo L., Milano G., Santini J., Demard F., Pierrefite V. Analysis of retinoic acid receptor β expression in normal and malignant laryngeal mucosa by a sensitive and routine applicable reverse transcription-polymerase chain reaction-linked immunosorbent assay method. Clin. Cancer Res. 3:1997;2137-2142.
15. Petit E., Milano G., Levi F., Thyss A., Bailleul F., Schneider M. Circadian rhythm varying plasma concentration of 5-fluorouracil during a five day continuous venous infusion at constant rate in cancer patients. Cancer Res. 48:1988;1976-1979.
16. Zhang R., Lu Z., Liu T., Soong S.J., Diasio R.B. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes. possible relevance to fluoropyrimidine chemotherapy Cancer Res. 53:1993;2816-2822.
17. Metzger G., Massari C., Etienne M.C.et al. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin relationship with mucosal toxicity in patients with cancer. Clin. Pharmacol. Ther. 56:1994;190-201.
18. Lévi F., Zidani R., Vannetzel J.M.et al. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multiinstitutional trial. J. Natl. Cancer Inst. 86:1994;1608-1617.
19. Lévi F., Zidani R., Misset J.L. Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 350:1997;681-686.
20. Curé H., Chevalier V., Adenis A.et al. Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. J. Clin. Oncol. 20:2002;1175-1181.
21. Naguib F.N.M., Soong S.J., El Kouni M.H. Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver. Possible relevance to chemotherapy with 5-fluoropyrimidines. Biochem. Pharmacol. 45:1993;667-673.
22. Haus E., Lakatua D., Swoyer J., Sackett-Lundeen L. Chronobiology in hematology and immunology. Am. J. Anat. 168:1983;467-517.
23. Tampellini M., Filipski E., Liu X.-H., Li X.-M., François E., Lévi F. Circadian rhythm in docetaxel tolerability and efficacy in mice. Cancer Res. 58:1998;3896-3904.
24. Shiotani T., Weber G. Purification and properties of dihydropyrimidine dehydrogenase from rat liver. J. Biol. Chem. 256:1981;219-224.
25. Queiroz-Claret C., Queiroz O. Multiple levels in the control of rhythms in enzyme synthesis and activity by circadian clocks. recent trends Chronobiol. Int. 7:1990;25-33.
26. Dunlap J. An end in the beginning. Science. 280:1998;1548-1549.
27. Gekakis N., Staknis D., Nguyen H.B.et al. Role of clock protein in the mammalian circadian mechanism. Science. 280:1998;1564-1567.
28. Foulkes N., Borjigin J., Snyder S.H., Sassone-Corsi P. Rhythmic transcription. the molecular basis of circadian melatonin synthesis Trends Neurosci. 20:1997;487-492.
29. Lakin-Thomas P.L. Circadian rhythms, new functions for old clock genes? Trends Genet. 16:2000;135-142.
30. Torra I.P., Tsibulsky V., Delaunay F.et al. Circadian and glucocorticoid regulation of Rev-erbalpha expression in liver. Endocrinology. 141:2000;3799-3806.
31. Collie-Duguid E.S.R., Johnston S.J., Powrie R.H.et al. Cloning and initial characterization of the human DPYD gene promoter. Biochem. Biophys. Res. Comm. 271:2000;28-35.